Institut Curie
@institutcurie.bsky.social
🌐 Internationally renowned #Research Center
🏥 State-of-the-art Hospital Group
🇨🇵 France's leading #cancer center
curie.fr
🏥 State-of-the-art Hospital Group
🇨🇵 France's leading #cancer center
curie.fr
Reposted by Institut Curie
Great day at @institutcurie.bsky.social for the Multiscale Integration in Biological Systems course! Thanks to the students for the great discussions and to the organizers for the kind invitation.
Always a pleasure to visit the historic Curie campus and catch up with colleagues
Always a pleasure to visit the historic Curie campus and catch up with colleagues
November 17, 2025 at 4:12 PM
Great day at @institutcurie.bsky.social for the Multiscale Integration in Biological Systems course! Thanks to the students for the great discussions and to the organizers for the kind invitation.
Always a pleasure to visit the historic Curie campus and catch up with colleagues
Always a pleasure to visit the historic Curie campus and catch up with colleagues
A study recently published in The Lancet Regional Health – Europe shows the impact of the French national multidisciplinary tumour board coordinated by @institutcurie.bsky.social with a demonstrated survival benefit for patients with cancer of unknown primary: www.thelancet.com/journals/lan...
November 13, 2025 at 3:02 PM
A study recently published in The Lancet Regional Health – Europe shows the impact of the French national multidisciplinary tumour board coordinated by @institutcurie.bsky.social with a demonstrated survival benefit for patients with cancer of unknown primary: www.thelancet.com/journals/lan...
📣 Discovery of a cellular resistance mechanism at the origin of relapses of triple-negative breast cancer: an essential step on the path towards more preventive medicine that is able to anticipate and avoid relapses.
▶️ institut-curie.org/news/relapse...
▶️ institut-curie.org/news/relapse...
November 12, 2025 at 11:00 AM
📣 Discovery of a cellular resistance mechanism at the origin of relapses of triple-negative breast cancer: an essential step on the path towards more preventive medicine that is able to anticipate and avoid relapses.
▶️ institut-curie.org/news/relapse...
▶️ institut-curie.org/news/relapse...
🎙️ Dans le bureau-jardin du Dr Manuel Rodrigues, littérature, botanique et science se rencontrent pour raconter une même histoire : celle des signatures de l’ADN, ces empreintes qui révèlent l’origine de certaines tumeurs.
Nouvel épisode de Têtes Chercheuses, à écouter sur : curie.fr/actualite/po...
Nouvel épisode de Têtes Chercheuses, à écouter sur : curie.fr/actualite/po...
November 12, 2025 at 9:49 AM
🎙️ Dans le bureau-jardin du Dr Manuel Rodrigues, littérature, botanique et science se rencontrent pour raconter une même histoire : celle des signatures de l’ADN, ces empreintes qui révèlent l’origine de certaines tumeurs.
Nouvel épisode de Têtes Chercheuses, à écouter sur : curie.fr/actualite/po...
Nouvel épisode de Têtes Chercheuses, à écouter sur : curie.fr/actualite/po...
🔈New crop of #ERC Synergy Grants for Institut Curie!
3 projects involving our researchers are on the list of winners of ERC Synergy Grants 2025: Nicolas Manel, Daniele Fachinetti, Stéphanie Descroix, Alexandre Baffet, Benoît Sorre, Leonid Mirny
➡️Learn more: institut-curie.org/news/new-cro...
#ERCSyG
3 projects involving our researchers are on the list of winners of ERC Synergy Grants 2025: Nicolas Manel, Daniele Fachinetti, Stéphanie Descroix, Alexandre Baffet, Benoît Sorre, Leonid Mirny
➡️Learn more: institut-curie.org/news/new-cro...
#ERCSyG
November 10, 2025 at 4:43 PM
🔈New crop of #ERC Synergy Grants for Institut Curie!
3 projects involving our researchers are on the list of winners of ERC Synergy Grants 2025: Nicolas Manel, Daniele Fachinetti, Stéphanie Descroix, Alexandre Baffet, Benoît Sorre, Leonid Mirny
➡️Learn more: institut-curie.org/news/new-cro...
#ERCSyG
3 projects involving our researchers are on the list of winners of ERC Synergy Grants 2025: Nicolas Manel, Daniele Fachinetti, Stéphanie Descroix, Alexandre Baffet, Benoît Sorre, Leonid Mirny
➡️Learn more: institut-curie.org/news/new-cro...
#ERCSyG
Published in @nature.com (Raphaël Rodrigez and team @institutcurie.bsky.social co-authors) ⬇️
Targeting FSP1 in the lymph nodes holds strong potential for blocking melanoma progression.
#ferroptosis #chembio
Targeting FSP1 in the lymph nodes holds strong potential for blocking melanoma progression.
#ferroptosis #chembio
Nature research paper: Lymph node environment drives FSP1 targetability in metastasizing melanoma
go.nature.com/49yHIAk
go.nature.com/49yHIAk
Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
go.nature.com
November 10, 2025 at 4:36 PM
Published in @nature.com (Raphaël Rodrigez and team @institutcurie.bsky.social co-authors) ⬇️
Targeting FSP1 in the lymph nodes holds strong potential for blocking melanoma progression.
#ferroptosis #chembio
Targeting FSP1 in the lymph nodes holds strong potential for blocking melanoma progression.
#ferroptosis #chembio
Reposted by Institut Curie
Join the advanced international course on
"Innovative approaches for pediatric cancer immunotherapy"
at the @institutcurie.bsky.social
January 28th - 30th , 2026
training.institut-curie.org/courses/inno...
"Innovative approaches for pediatric cancer immunotherapy"
at the @institutcurie.bsky.social
January 28th - 30th , 2026
training.institut-curie.org/courses/inno...
Innovative approaches for pediatric cancer immunotherapy | Institut Curie Advanced Training
This course aims to synthesize the state-of-the-art and the therapeutic perspectives related to harnessing children's immune system to target pediatric tumors. Encompassing topics from biological char...
training.institut-curie.org
November 2, 2025 at 7:10 AM
Join the advanced international course on
"Innovative approaches for pediatric cancer immunotherapy"
at the @institutcurie.bsky.social
January 28th - 30th , 2026
training.institut-curie.org/courses/inno...
"Innovative approaches for pediatric cancer immunotherapy"
at the @institutcurie.bsky.social
January 28th - 30th , 2026
training.institut-curie.org/courses/inno...
Reposted by Institut Curie
#Communiqué 🗞️ Un mécanisme de résistance cellulaire à l’origine de rechutes du cancer du sein triple négatif vient d’être découvert. Cette découverte est une étape clé pour anticiper et éviter les rechutes dans les cancers les plus agressifs.
👉 www.cnrs.fr/fr/presse/re...
👉 www.cnrs.fr/fr/presse/re...
November 6, 2025 at 4:43 PM
#Communiqué 🗞️ Un mécanisme de résistance cellulaire à l’origine de rechutes du cancer du sein triple négatif vient d’être découvert. Cette découverte est une étape clé pour anticiper et éviter les rechutes dans les cancers les plus agressifs.
👉 www.cnrs.fr/fr/presse/re...
👉 www.cnrs.fr/fr/presse/re...
👏 Double success for @institutcurie.bsky.social & @minesparis-psl.bsky.social at MIDOG 2025: Prof. @thomas-walter.bsky.social team ranks 1st in mitosis classification and 2nd in detection, standing out among the leading groups in artificial intelligence applied to medical image analysis.
October 30, 2025 at 3:07 PM
👏 Double success for @institutcurie.bsky.social & @minesparis-psl.bsky.social at MIDOG 2025: Prof. @thomas-walter.bsky.social team ranks 1st in mitosis classification and 2nd in detection, standing out among the leading groups in artificial intelligence applied to medical image analysis.
🎧 Nouvelle saison de Têtes Chercheuses !
Sarah Watson, oncologue et chercheuse à l’Institut Curie, est spécialiste des cancers rares. Au micro de Zoé Varier, elle raconte la complexité de ces maladies et la dimension humaine qui la guide.
🎙️ À écouter dès maintenant : curie.fr/actualite/po...
Sarah Watson, oncologue et chercheuse à l’Institut Curie, est spécialiste des cancers rares. Au micro de Zoé Varier, elle raconte la complexité de ces maladies et la dimension humaine qui la guide.
🎙️ À écouter dès maintenant : curie.fr/actualite/po...
October 28, 2025 at 10:22 AM
🎧 Nouvelle saison de Têtes Chercheuses !
Sarah Watson, oncologue et chercheuse à l’Institut Curie, est spécialiste des cancers rares. Au micro de Zoé Varier, elle raconte la complexité de ces maladies et la dimension humaine qui la guide.
🎙️ À écouter dès maintenant : curie.fr/actualite/po...
Sarah Watson, oncologue et chercheuse à l’Institut Curie, est spécialiste des cancers rares. Au micro de Zoé Varier, elle raconte la complexité de ces maladies et la dimension humaine qui la guide.
🎙️ À écouter dès maintenant : curie.fr/actualite/po...
📣 Registration for the next international course at
@institutcurie.bsky.social on the innovative approaches for pediatric cancer immunotherapy is now open, until november 28th, 2025.
🗓️ January 28 - 30, 2026
▶️ More info: training.institut-curie.org/courses/inno...
@institutcurie.bsky.social on the innovative approaches for pediatric cancer immunotherapy is now open, until november 28th, 2025.
🗓️ January 28 - 30, 2026
▶️ More info: training.institut-curie.org/courses/inno...
October 23, 2025 at 10:19 AM
📣 Registration for the next international course at
@institutcurie.bsky.social on the innovative approaches for pediatric cancer immunotherapy is now open, until november 28th, 2025.
🗓️ January 28 - 30, 2026
▶️ More info: training.institut-curie.org/courses/inno...
@institutcurie.bsky.social on the innovative approaches for pediatric cancer immunotherapy is now open, until november 28th, 2025.
🗓️ January 28 - 30, 2026
▶️ More info: training.institut-curie.org/courses/inno...
⏳ Last days to register to the Development & Cancer course at @institutcurie.bsky.social! Discover the current knowledge linking developmental biology with the cellular and molecular study of cancers with international experts.
Register now ▶️ training.institut-curie.org/courses/deve...
Register now ▶️ training.institut-curie.org/courses/deve...
October 22, 2025 at 9:21 AM
⏳ Last days to register to the Development & Cancer course at @institutcurie.bsky.social! Discover the current knowledge linking developmental biology with the cellular and molecular study of cancers with international experts.
Register now ▶️ training.institut-curie.org/courses/deve...
Register now ▶️ training.institut-curie.org/courses/deve...
🎙️ Le podcast de l'Institut Curie est de retour pour une deuxième saison ! RDV le 28 octobre pour 6 nouveaux épisodes qui vous feront plonger dans les laboratoires de l’Institut Curie et découvrir la science autrement. 👀
October 21, 2025 at 2:32 PM
🎙️ Le podcast de l'Institut Curie est de retour pour une deuxième saison ! RDV le 28 octobre pour 6 nouveaux épisodes qui vous feront plonger dans les laboratoires de l’Institut Curie et découvrir la science autrement. 👀
Registration for the next international course at @institutcurie.bsky.social is open, until november 14th. This 2nd edition will focus on understanding the molecular basis of urothelial tumors to improve diagnosis and treatment.
📅 January 14-16, 2026
▶️ training.institut-curie.org/courses/urot...
📅 January 14-16, 2026
▶️ training.institut-curie.org/courses/urot...
October 21, 2025 at 10:09 AM
Registration for the next international course at @institutcurie.bsky.social is open, until november 14th. This 2nd edition will focus on understanding the molecular basis of urothelial tumors to improve diagnosis and treatment.
📅 January 14-16, 2026
▶️ training.institut-curie.org/courses/urot...
📅 January 14-16, 2026
▶️ training.institut-curie.org/courses/urot...
Reposted by Institut Curie
[RDV 16h !] Le risque de cancers chez les jeunes augmente. Quels types de cancers ? Quels facteurs et quelles causes ? tinyurl.com/2s4k242a On en parle avec Emmanuelle Fourme et Cindy Neuzillet @institutcurie.bsky.social #ScienceCQFD
October 21, 2025 at 9:53 AM
[RDV 16h !] Le risque de cancers chez les jeunes augmente. Quels types de cancers ? Quels facteurs et quelles causes ? tinyurl.com/2s4k242a On en parle avec Emmanuelle Fourme et Cindy Neuzillet @institutcurie.bsky.social #ScienceCQFD
#ESMO25 | Studies of the French national coordination on unknown primary cancers (CUP) led by Institut Curie show the importance of a collaborative and multidisciplinary approach to improve targeted treatments in these rare cancers.
Learn more:
➡️ institut-curie.org/esmo2025
#OncSky #CUP
Learn more:
➡️ institut-curie.org/esmo2025
#OncSky #CUP
October 20, 2025 at 4:46 PM
#ESMO25 | Studies of the French national coordination on unknown primary cancers (CUP) led by Institut Curie show the importance of a collaborative and multidisciplinary approach to improve targeted treatments in these rare cancers.
Learn more:
➡️ institut-curie.org/esmo2025
#OncSky #CUP
Learn more:
➡️ institut-curie.org/esmo2025
#OncSky #CUP
#ESMO25 | New insights from the IMMUNOBIL phase II trial presented by Dr Matthieu Delaye (Institut Curie): a combination of 2 immunotherapies in advanced biliary tract cancer after platinum-based chemo shows promising survival for a subgroup of patients.
➡️ institut-curie.org/esmo2025
➡️ institut-curie.org/esmo2025
October 20, 2025 at 2:27 PM
#ESMO25 | New insights from the IMMUNOBIL phase II trial presented by Dr Matthieu Delaye (Institut Curie): a combination of 2 immunotherapies in advanced biliary tract cancer after platinum-based chemo shows promising survival for a subgroup of patients.
➡️ institut-curie.org/esmo2025
➡️ institut-curie.org/esmo2025
#ESMO25 | Physicians and researchers from @institutcurie.bsky.social delighted to share their latest advances, innovations, and expertise to accelerate discoveries in #oncology for the benefit of patients 🤝
Learn more:
📍https://institut-curie.org/esmo2025
📍Booth Institut Curie / Hall 2.2b - #2036
Learn more:
📍https://institut-curie.org/esmo2025
📍Booth Institut Curie / Hall 2.2b - #2036
October 20, 2025 at 9:59 AM
#ESMO25 | Physicians and researchers from @institutcurie.bsky.social delighted to share their latest advances, innovations, and expertise to accelerate discoveries in #oncology for the benefit of patients 🤝
Learn more:
📍https://institut-curie.org/esmo2025
📍Booth Institut Curie / Hall 2.2b - #2036
Learn more:
📍https://institut-curie.org/esmo2025
📍Booth Institut Curie / Hall 2.2b - #2036
#ESMO25 | New insights from the SOHO-01 study presented by Prof. NIcolas Girard @institutcurie.bsky.social:
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
October 19, 2025 at 1:13 PM
#ESMO25 | New insights from the SOHO-01 study presented by Prof. NIcolas Girard @institutcurie.bsky.social:
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
Molecular factors and ctDNA dynamics may help predict outcomes in patients with HER2-mutant #NSCLC treated with sevabertinib, paving the way for more personalized care.
#medonc #lungcancer
#ESMO25 | Uveal melanoma: positive results of the phase 2 PLUME clinical trial, presented by Dr. Manuel Rodrigues @institutcurie.bsky.social (efficacy and tolerability of immunotherapy anti-PD-1 + targeted treatment)
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
October 18, 2025 at 4:56 PM
#ESMO25 | Uveal melanoma: positive results of the phase 2 PLUME clinical trial, presented by Dr. Manuel Rodrigues @institutcurie.bsky.social (efficacy and tolerability of immunotherapy anti-PD-1 + targeted treatment)
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
➡️ Learn more:
institut-curie.org/news/metasta...
#medonc #oncalert
#ESMO25 | Promising real-world data from the french multicenter LARENA study presented by Dr Diana Bello-Roufai @institutcurie.bsky.social, show that adapting pembrolizumab-lenvatinib dosing in metastatic endometrial cancer reduces toxicity without compromising efficacy.
#medonc
#medonc
October 18, 2025 at 11:50 AM
#ESMO25 | Promising real-world data from the french multicenter LARENA study presented by Dr Diana Bello-Roufai @institutcurie.bsky.social, show that adapting pembrolizumab-lenvatinib dosing in metastatic endometrial cancer reduces toxicity without compromising efficacy.
#medonc
#medonc
#ESMO2025 | Finding Less Toxic Treatments for Women with Hormone-Dependent #BreastCancer.
Pr Paul Cottu (Institut Curie) presented preliminary results from the RIBOLARIS study, showing that in 52% of pts, chemotherapy could be replaced with a less toxic treatment
👉 institut-curie.org/news/less-to...
Pr Paul Cottu (Institut Curie) presented preliminary results from the RIBOLARIS study, showing that in 52% of pts, chemotherapy could be replaced with a less toxic treatment
👉 institut-curie.org/news/less-to...
October 17, 2025 at 2:35 PM
#ESMO2025 | Finding Less Toxic Treatments for Women with Hormone-Dependent #BreastCancer.
Pr Paul Cottu (Institut Curie) presented preliminary results from the RIBOLARIS study, showing that in 52% of pts, chemotherapy could be replaced with a less toxic treatment
👉 institut-curie.org/news/less-to...
Pr Paul Cottu (Institut Curie) presented preliminary results from the RIBOLARIS study, showing that in 52% of pts, chemotherapy could be replaced with a less toxic treatment
👉 institut-curie.org/news/less-to...
📍 Expert scientists and clinicians of Institut Curie are attending #ESMO25, Europe’s key #oncology congress.
They’ll share promising results in breast cancer, uveal melanoma, cancers of unknown origin, and new therapeutic innovations for patients.
👉 institut-curie.org/esmo2025 @myesmo.bsky.social
They’ll share promising results in breast cancer, uveal melanoma, cancers of unknown origin, and new therapeutic innovations for patients.
👉 institut-curie.org/esmo2025 @myesmo.bsky.social
October 17, 2025 at 2:22 PM
📍 Expert scientists and clinicians of Institut Curie are attending #ESMO25, Europe’s key #oncology congress.
They’ll share promising results in breast cancer, uveal melanoma, cancers of unknown origin, and new therapeutic innovations for patients.
👉 institut-curie.org/esmo2025 @myesmo.bsky.social
They’ll share promising results in breast cancer, uveal melanoma, cancers of unknown origin, and new therapeutic innovations for patients.
👉 institut-curie.org/esmo2025 @myesmo.bsky.social
Registration is open for the next Genome Dynamics course at @institutcurie.bsky.social! This course will explore the full spectrum of genome biology bringing together international experts to share the latest experimental and computational advances ▶️ training.institut-curie.org/courses/Geno...
October 14, 2025 at 9:14 AM
Registration is open for the next Genome Dynamics course at @institutcurie.bsky.social! This course will explore the full spectrum of genome biology bringing together international experts to share the latest experimental and computational advances ▶️ training.institut-curie.org/courses/Geno...
A key mechanism behind Mycobacterium tuberculosis survival:
Researchers, including Dr. Ting-Di Wu from Institut Curie, found that the bacterium depends on a unique sulfate transporter — a potential target for new treatments without side effects on human cells.
🔗 www.pnas.org/doi/abs/10.1...
Researchers, including Dr. Ting-Di Wu from Institut Curie, found that the bacterium depends on a unique sulfate transporter — a potential target for new treatments without side effects on human cells.
🔗 www.pnas.org/doi/abs/10.1...
October 7, 2025 at 2:24 PM
A key mechanism behind Mycobacterium tuberculosis survival:
Researchers, including Dr. Ting-Di Wu from Institut Curie, found that the bacterium depends on a unique sulfate transporter — a potential target for new treatments without side effects on human cells.
🔗 www.pnas.org/doi/abs/10.1...
Researchers, including Dr. Ting-Di Wu from Institut Curie, found that the bacterium depends on a unique sulfate transporter — a potential target for new treatments without side effects on human cells.
🔗 www.pnas.org/doi/abs/10.1...